Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

被引：0

作者：

Fernandez, E. ^{[1
]}

Vernet, R. ^{[2
]}

Charrier, E. ^{[3
]}

Migliorini, D. M. ^{[4
]}

Urwyler, M. ^{[2
]}

Belkouch, M-C. ^{[2
]}

Von Rohr, O. ^{[5
]}

Saingier, V. ^{[5
]}

Ancrenaz, V. ^{[5
]}

Grandjean, N. ^{[6
]}

Lafferma, E. ^{[6
]}

Lavalliere, E. ^{[6
]}

Rubin, O. ^{[7
]}

Villard, J. ^{[8
]}

Grogg, J. N. ^{[9
]}

Mach, N. ^{[10
]}

机构：

[1] HUG Hopitaux Univ Geneve, Dept Oncol, Geneva, Switzerland

[2] HUG Hopitaux Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[3] UNIGE Univ Geneve, Cell Based Immunotherapy Iab, Oncol, Ctr Med Univ CMU, Geneva, Switzerland

[4] Hop Univ Geneve HUG, Oncol, Geneva, Switzerland

[5] HUG Hop Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[6] HUG Hop Univ Geneve, Clin Res Unit, Oncol, Geneva, Switzerland

[7] HUG Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[8] Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[9] MaxiVax SA, R&D, Geneva, Switzerland

[10] HUG Hop Univ Geneve, Oncol, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.888

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

762P

引用

页码：S891 / S891

页数：1

共 50 条

[31] Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas
Shivaani Kummar
Martin E. Gutierrez
Lawrence W. Anderson
Raymond W. Klecker
Alice Chen
Anthony J. Murgo
James H. Doroshow
Jerry M. Collins
Cancer Chemotherapy and Pharmacology, 2013, 72 : 917 - 923
[32] Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas
Kummar, Shivaani
Gutierrez, Martin E.
Anderson, Lawrence W.
Klecker, Raymond W., Jr.
Chen, Alice
Murgo, Anthony J.
Doroshow, James H.
Collins, Jerry M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 917 - 923
[33] SAFETY, EFFICACY, AND PHARMACOKINETIC RESULTS FROM A PHASE I FIRST-IN-HUMAN STUDY OF ABBV-151 WITH OR WITHOUT ANTI-PD1 MAB (BUDIGALIMAB) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Tolcher, Anthony
Roda-Perez, Desamparados
He, Kai
Moreno, Victor
Gomez-Roca, Carlos
Machiels, Jean-Pascal
Razak, Albiruni
Sahtout, Mohammad
Guan, Xiaowen
Jaryno-Daly, Stacy
Leibman, Rachel
Blaney, Martha
O'Brien, James
Lorusso, Patricia
Powderly, John
Golan, Talia
Miller, Kathy
Bruix, Jordi
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A801 - A801
[34] Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors
Goetze, T. O.
Daniel, M. W.
Rafiyan, M-R.
Kiselicki, D.
Habibzade, T.
Schaaf, M.
Eickhoff, R.
Jaeger, E.
Al-Batran, S-E.
ANNALS OF ONCOLOGY, 2021, 32 : S843 - S843
[35] A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors
Ahnert, Jordi Rodon
Gruber, Joshua James
Telli, Melinda L.
Mita, Monica M.
Mita, Alain C.
Kim, Joseph W.
Villalona-Calero, Miguel Angel
Patel, Meera
Yadav, Shalini S.
Sharma, Padmanee
Haber, Tom
Lauren, Jessica
Seet, Symons Qihui
Dharmadhikari, Bhushan
Thakkar, Dipti
Kwek, Kon Yew
DiMascio, Leah
Rowinsky, Eric Keith
Ingram, Piers
Boyd-Kirkup, Jerome Douglas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Feasibility of eftilagimod alpha combined with avelumab in advanced solid tumors: advanced safety and efficacy data from Stratum D of the phase I INSIGHT platform trial
Goetze, Thorsten O.
Mueller, Daniel W.
Rafiyan, Mohammad-Reza
Kiselicki, Dragan
Habibzade, Timursah
Schaaf, Marina
Sookthai, Disorn
Eickhoff, Regina
Jager, Elke
Al-Batran, Salah-Eddin
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 51 - 51
[37] Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors
Coward, Jim
Kichenadasse, Ganessan
Park, John J.
Parakh, Sagun
Richardson, Gary Edward
Voskoboynik, Mark
Powderly, John D., II
Song, Zhengbo
Liu, Shutong
Huang, Yaling
Liu, Shu-Hui
Meng, Xun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[38] Feasibility of eftilagimod alpha combined with avelumab in advanced solid tumors: advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial
Goetze, T. O.
Mueller, D. W.
Rafiyan, M. R.
Kiselicki, D.
Habibzade, T.
Schaaf, M.
Eickhoff, R.
Jaeger, E.
Al-Batran, S. E.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 227 - 228
[39] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
Varga, Andreea
Baldini, Capucine
Martin-Romano, Patricia
Besse, Benjamin
Planchard, David
Champiat, Stephane
Angevin, Eroc
Hollebecque, Antoine
Bahleda, Rastislav
Gazzah, Anas
Armand, Jean-Pierre
Paoletti, Xavier
Massard, Christophe
Soria, Jean-Charles
Marabelle, Aurelien
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
Coward, Jermaine
Ganju, Vinod
Behzadigohar, Ramin
Kwong, Kenneth
Xu, June
Van, Hardy
Kong, Paul
Yang, Fei
Chen, Lisa
Guo, Kangping
Liu, Mei
Zhu, Danming
Donato, Lara Kristina
Xu, Ting
Richardson, Gary Edward
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →